Evaluation of Cryoprotection Induced Nail Toxicity Docetaxel Low Cumulative Dose

Inclusion Criteria: * upper age to 18 years * mammary adenocarcinoma nonmetastatic and histologically proven * wait under an adjuvant or neoadjuvant chemotherapy according to the following conventional scheme: 3 cycles of F5-Fluorouracil, epirubicin and cyclophosphamide 100 (500 or 5-Fluorouracil 600 mg / m² J1, Epirubicin 100 mg / m² J1, Cyclophosphamide 500 or 600 mg / m² J1 or 3 cycles of Epiribucin and Cyclophosphamide 100) followed by 3 cycles of docetaxel, 100 mg / m², +/- trastuzumab if Her2+++ * Patient with the capacity/faculties to understand a newsletter and sign an informed consent * Patient receiving social coverage * Patient who can be treated and followed in the center for a period of at least one year * WHO scale 0 or 1 Exclusion Criteria: * Age below 18 years * Diseases of the scalp or whatever hair-showing against helmet or alopecia * Using pre nail resin before and per chemotherapy * mammary adenocarcinoma stage IV * Indication of docetaxel for cancer of another organ than breast * Treatment processing or programmed during chemotherapy with an innovative molecule being evaluated * Raynaud's syndrome, cold agglutinin disease, cryoglobulinemia and cryofibrinogenemia. * Uncontrolled severe arterial disease. * Presence of a device\> grade 1 neuropathy before the start of chemotherapy * Patient unable to submit the protocol followed for psychological, social, family or geographical * Patient with an incompatible underlying disease or concomitant with the inclusion in the trial, whether psychiatric or somatic * Patient trust, guardianship, under legal protection measure, deprived of freedom * Male * Criteria for non randomization (before the first course of docetaxel) : * Presence of peripheral neuropathy\> grade 1 after the first 3 cycles of 5-Fluorouracil, epirubicin and cyclophosphamide 100. * Presence of a nail or skin toxicity\> grade 1 after 3 cycles of 5-Fluorouracil, epirubicin and cyclophosphamide 100.